Article
Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
The Prostate - 1 May 2010
Kristal Alan R, Price Douglas K, Till Cathee, Schenk Jeannette M, Neuhouser Marian L, Ockers Sandy, Lin Daniel W, Thompson Ian M, Figg William D
Abstract excerpt
BACKGROUND: To examine whether androgen receptor (AR) CAG repeat length was associated with the risk of incident benign prostatic hyperplasia (BPH). METHODS: A nested case-control study of 416 BPH cases and 527 controls drawn from Prostate Cancer Prevention Trial placebo-arm participants who were free of BPH at baseline. BPH was assessed over 7 years and was defined as receipt of medical or surgical treatment,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.